The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment
Triple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Journal of Nanomaterials |
Online Access: | http://dx.doi.org/10.1155/2020/4943270 |
id |
doaj-aa6e9e21e3b0489486242bf3bfa4ff98 |
---|---|
record_format |
Article |
spelling |
doaj-aa6e9e21e3b0489486242bf3bfa4ff982020-11-25T03:27:49ZengHindawi LimitedJournal of Nanomaterials1687-41101687-41292020-01-01202010.1155/2020/49432704943270The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer TreatmentYi-Zhi Zhu0Di Xu1Zhen Liu2Tian Tian3Fei Deng4Wen-Juan Tang5Yang Wu6Wei Zhang7Jin-Hai Tang8Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaSchool of Clinical Medicine, Xuzhou Medical University, Xuzhou 221004, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, ChinaTriple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new target treatment strategies for TNBC are of urgent need. It was speculated that glutamine could be a potential target because it is in high demand by TNBC. In this study, we found that the transporter for glutamine, ASCT2 (solute carrier family 1 member 5 (SLC1A5)), is highly expressed in TNBC by analysis of data from The Cancer Genome Atlas (TCGA) and experiments in vitro. Based on this, glutamine was grafted onto a polymeric drug carrier in order to develop a tumor-targeting drug delivery system for treatment of TNBC. Firstly, pH-responsive glutamine-PEG5000-b-PAE10000 (Gln-PEG-b-PAE) copolymers were synthesized using Fmoc-PEG5000-b-PAE10000 (Fmoc-PEG-b-PAE) copolymers. Then, Gln-PEG-b-PAE@DOX micelles were prepared by loading DOX to Gln-PEG-b-PAE copolymer using a solvent casting technology. In vitro, Gln-PEG-b-PAE@DOX micelles exhibited pH-dependent micellization-decellularization behavior; namely, they can rapidly release DOX in acidic environment of pH 6.0 but release very slowly in physiological condition. Moreover, glutamine competition experiment showed that Gln-PEG-b-PAE@DOX micelles had the ability to target MDA-MB-231 cells. Compared to free DOX, Gln-PEG-b-PAE@DOX micelles had significantly greater cytotoxic effect and antiproliferative activity against MDA-MB-231 cells. In vivo, compared to free DOX and mPEG-b-PAE@DOX micelles, Gln-PEG-b-PAE@DOX micelles significantly inhibited tumor growth in tumor-bearing mice. Therefore, Gln-PEG-b-PAE@DOX micelles, as a tumor-targeting drug delivery system, may provide a new method for the treatment of TNBC.http://dx.doi.org/10.1155/2020/4943270 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yi-Zhi Zhu Di Xu Zhen Liu Tian Tian Fei Deng Wen-Juan Tang Yang Wu Wei Zhang Jin-Hai Tang |
spellingShingle |
Yi-Zhi Zhu Di Xu Zhen Liu Tian Tian Fei Deng Wen-Juan Tang Yang Wu Wei Zhang Jin-Hai Tang The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment Journal of Nanomaterials |
author_facet |
Yi-Zhi Zhu Di Xu Zhen Liu Tian Tian Fei Deng Wen-Juan Tang Yang Wu Wei Zhang Jin-Hai Tang |
author_sort |
Yi-Zhi Zhu |
title |
The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment |
title_short |
The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment |
title_full |
The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment |
title_fullStr |
The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment |
title_full_unstemmed |
The Synthesis of Glutamine-Functionalized Block Polymer and Its Application in Triple-Negative Breast Cancer Treatment |
title_sort |
synthesis of glutamine-functionalized block polymer and its application in triple-negative breast cancer treatment |
publisher |
Hindawi Limited |
series |
Journal of Nanomaterials |
issn |
1687-4110 1687-4129 |
publishDate |
2020-01-01 |
description |
Triple-negative breast cancer (TNBC) is a highly malignant tumor. At present, there are still no targeted drugs for TNBC. Clinical chemotherapeutic drugs, such as doxorubicin (DOX), have the characteristic of nontargeted distribution in treatment of TNBC, causing severe side effects. Therefore, new target treatment strategies for TNBC are of urgent need. It was speculated that glutamine could be a potential target because it is in high demand by TNBC. In this study, we found that the transporter for glutamine, ASCT2 (solute carrier family 1 member 5 (SLC1A5)), is highly expressed in TNBC by analysis of data from The Cancer Genome Atlas (TCGA) and experiments in vitro. Based on this, glutamine was grafted onto a polymeric drug carrier in order to develop a tumor-targeting drug delivery system for treatment of TNBC. Firstly, pH-responsive glutamine-PEG5000-b-PAE10000 (Gln-PEG-b-PAE) copolymers were synthesized using Fmoc-PEG5000-b-PAE10000 (Fmoc-PEG-b-PAE) copolymers. Then, Gln-PEG-b-PAE@DOX micelles were prepared by loading DOX to Gln-PEG-b-PAE copolymer using a solvent casting technology. In vitro, Gln-PEG-b-PAE@DOX micelles exhibited pH-dependent micellization-decellularization behavior; namely, they can rapidly release DOX in acidic environment of pH 6.0 but release very slowly in physiological condition. Moreover, glutamine competition experiment showed that Gln-PEG-b-PAE@DOX micelles had the ability to target MDA-MB-231 cells. Compared to free DOX, Gln-PEG-b-PAE@DOX micelles had significantly greater cytotoxic effect and antiproliferative activity against MDA-MB-231 cells. In vivo, compared to free DOX and mPEG-b-PAE@DOX micelles, Gln-PEG-b-PAE@DOX micelles significantly inhibited tumor growth in tumor-bearing mice. Therefore, Gln-PEG-b-PAE@DOX micelles, as a tumor-targeting drug delivery system, may provide a new method for the treatment of TNBC. |
url |
http://dx.doi.org/10.1155/2020/4943270 |
work_keys_str_mv |
AT yizhizhu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT dixu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT zhenliu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT tiantian thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT feideng thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT wenjuantang thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT yangwu thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT weizhang thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT jinhaitang thesynthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT yizhizhu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT dixu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT zhenliu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT tiantian synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT feideng synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT wenjuantang synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT yangwu synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT weizhang synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment AT jinhaitang synthesisofglutaminefunctionalizedblockpolymeranditsapplicationintriplenegativebreastcancertreatment |
_version_ |
1715208118414082048 |